Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanoplast DHAAM (Dehydrated Human Amniotic Membrane) is a sterile, acellular extracellular matrix (ECM) scaffold developed by BioXtek. Derived from donated human placental tissue (amniotic and/or chorion membranes), the product is processed through decellularization and dehydration before terminal sterilization via irradiation. It is registered as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR Part 1271 Section 361 for homologous use as a barrier or cover. Sanoplast DHAAM is indicated for a variety of clinical uses, including the treatment of dry eye syndrome, topical wounds, stage 1 and 2 diabetic ulcers, tendon and nerve repairs, dura replacement in neurosurgery, and pericardial coverage. The matrix supports tissue regeneration by providing a stable environment for cell migration and proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanoplast DHAAM.